Decibel Therapeutics Reports Positive Data from Interim Anal

- 87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020-treated ear – - Data support continued development of DB-020 as a... | June 28, 2022

Related Keywords

Boston , Massachusetts , United States , Australia , Brisbane , Queensland , Melbourne , Victoria , American , Danny Rischin , Julie Seidel , John Lee , Laurence Reid , Ben Panizza , Chris Railey , Division Of Cancer Medicine , Exchange Commission , Stern Ir Inc , Neck Cancer Centre , Twitter , Chief Development Officer , American Speech Language Hearing Association , Speech Intelligibility Index , Cancer Medicine , Medical Oncology , Peter Maccallum Cancer Centre , Queensland Head , Chief Executive Officer , Decibel Therapeutics , Private Securities Litigation Reform Act , Quarterly Report , Nc Stock Exchange , News , Information , Press Release , F , Patients , Who , Xperienced , Cytotoxicity , N , Their , Ear , Were , Protected , Rom , Data , Support , Ontinued , Development , S Dbtx Us24343r1068 ,